esomeprazole (Nexium®) + Xolaam®
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout esomeprazole (Nexium®) + Xolaam®
esomeprazole (Nexium®) + Xolaam® is a approved stage product being developed by AstraZeneca for GERD. The current trial status is completed. This product is registered under clinical trial identifier NCT00444275. Target conditions include GERD.
What happened to similar drugs?
8 of 20 similar drugs in GERD were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00444275 | Approved | Completed |
Competing Products
20 competing products in GERD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OMEZ 40 + OMEZ 80 | Dr. Reddy's Laboratories | Approved | 40 |
| omeprazole+domperidone SR + omeprazole | Dr. Reddy's Laboratories | Approved | 36 |
| Rabeprazole ER + Ranitidine | Eisai | Phase 3 | 40 |
| Rabeprazole sodium | Eisai | Phase 1 | 29 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 40 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 40 |
| Rabeprazole ER + Ranitidine | Eisai | Phase 3 | 40 |
| Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg | Eisai | Phase 1 | 29 |
| rabeprazole + rabeprazole | Eisai | Phase 3 | 40 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 40 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 40 |
| ONO-8539 | Ono Pharmaceutical | Phase 1 | 29 |
| esomeprazole 40 mg | Johnson & Johnson | Pre-clinical | 26 |
| esomeprazole | AstraZeneca | Pre-clinical | 26 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| esomeprazole magnesium | AstraZeneca | Phase 1 | 29 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| Esomeprazole | AstraZeneca | Phase 3 | 40 |
| Esomeprazole (Nexium) | AstraZeneca | Approved | 43 |